Confusing guidance [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-09-25 09:52  – Posting: # 20647
Views: 1,565

Hi Mutasim,

reading the guidance again I understand your confusion.

On top of page 3 we have

Background: Ezetimibe undergoes extensive pre-systemic metabolism; ezetimibe-glucuronide is the major active metabolite. Because of extensive hepatic recirculation, the exposure to ezetimibe is less representative to evaluate absorption.

And then

Bioequivalence assessment: Background/justification: On total (parent + glucuronide metabolite together)

(my emphases)

Analyte:both seemingly tells us to measure them separately but the remainder tells us that only the total should be assessed for BE. So why all that fuzz?

I still think that cleaving by glucuronidase and analyzing ezetimibe is the way to go. What I wrote above was based on extraction techniques (SPE, LLE). If you opt for protein precipation it could work but as a hydrophilic compound it might well be that some part of the glucuronide gets trapped in the precipitate. I also believe that you need two chromatographic conditions. Furthermore, glucuronides are known for back-conversion in the ion-source. Hence, what you might get are wrong values for both the parent and the metabolite but the sum will be correct (assuming that nothing of the glucuronide gets trapped – what I doubt). Hence, I would keep it simple and go for cleavage and have just one run.
If the EMA really want both separatelly IMHO, it would have been better to state in the GL:


Out of curiosity: Since dealing with glucuronides was the topic of my first paper* – which stationary & mobile phase are you using?

Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
20,237 posts in 4,258 threads, 1,396 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 23:52 UTC

Nothing shocks me. I’m a scientist.    Harrison Ford (as Indiana Jones)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz